Biotech & Venture Capital
Apogee Secures Up to $1.3 Billion From Blackstone to Advance Eczema Drug
By Intent.Health Team • May 27, 2026
What’s happening
Apogee Therapeutics secured up to $1.3 billion from Blackstone to help develop its eczema treatment.
The deal provides Apogee with massive financial backing, establishing a path forward without relying on a traditional pharmaceutical corporate acquisition.
What’s changing / Business impact
This high-profile capital injection accelerates new trends in biotech market capitalization:
- Increased adoption of alternative biotech financing frameworks
- Deeper investment-firm involvement directly within therapeutic drug development cycles
- Continued infrastructure and pipeline growth across inflammatory disease treatments
Why this matters
Eczema drugs have expanded into a massive global pharmaceutical sector because chronic inflammatory diseases actively affect millions of patients worldwide.
This transaction proves private investment firms are playing substantially larger roles in primary healthcare innovation, demonstrating that modern biotech financing models are rapidly evolving beyond traditional big pharma partnerships.